



Achillion Pharmaceuticals  
Investor Relations Department  
300 George St.  
New Haven, CT 06511  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

**NASDAQ: ACHN**

Last Trade:	4.38
Trade Time:	4:00 PM ET Jun 23, 2017
Change:	0.08 <span style="color: green;">↑</span> (+1.860%)
Day Range	4.26 - 4.40
52-Week Range	3.15 - 9.50
Volume	5,220,406

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile


Rooted in the myth of Achilles, the name of Achillion refers to the brave warrior committed to a cause as well as the company's mission to combat diseases by identifying and exploiting their unique vulnerabilities.

### Inspiring Science. Innovative Medicine.

Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is a science-driven, patient-focused company leveraging its strengths across the continuum from drug discovery to commercialization to provide better treatments for people with serious diseases.

... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Jun 15, 2017*

[Achillion to Present at the 2017 JMP Securities Life Sciences Conference](#)

*Jun 5, 2017*

[Achillion to Present at the Jefferies 2017 Global Healthcare Conference](#)

*May 4, 2017*

[Achillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs](#)

*May 2, 2017*

[Achillion to Present at the Deutsche Bank 42nd Annual Health Care Conference](#)

*Apr 22, 2017*

[Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178](#)

## Financial Disclosures [\[ View all \]](#)

[First Quarter Financial Results](#)

*Feb 23, 2017*

[Annual Report \(10-K\)](#)

*Apr 17, 2017*

[Proxy Statement \(DEF 14A\)](#)

*May 4, 2017*

[Quarterly Report \(10-Q\)](#)

*Nov 3, 2016*

[Quarterly Report \(10-Q\)](#)

*Aug 4, 2016*

[Quarterly Report \(10-Q\)](#)